Immuno-effect of Tα1 for Stage I NSCLC
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).
Non Small Cell Lung Cancer
DRUG: Thymosin Alpha1
Number of CTCs, Number of peripheral blood circulating tumor cells after Tα1 treatment, 4 months after sugery
Number of immune cells, Number of TERT+ immnue cells after Tα1 treatment, 4 months after sugery|Peripheral blood immune cells profile, Number of immune cells profile, including but limited to CD4+, CD8+, T cells, 4 months after sugery|AE, the safety profile of the Tα1 treatment, within 4 months after sugery
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).